Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407563 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
A Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 11
- Study locations
NCT00407563: Completed Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma, sponsored by Accelerated Community Oncology Research Network.
NCT00407563 is a Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 48 participants, below the 210-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00407563, a Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
Primary Outcome
Progression-free rate is defined as the percentage of participants with no progression event at 6 months after starting study treatment. An event for this endpoint was defined as a progression-free survival event occurring earlier than six months, or discontinuation of treatment earlier than six months for any other reason. Progression is defined per RECIST criteria v1.0 as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the app
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Abraxane
Study Locations (11)
Georgia
- Northeast Georgia Cancer Care, LLC - Athens
- Southeastern Gynecologic Oncology, LLC - Atlanta
Tennessee
- Chattanooga's Program in Women's Oncology - Chattanooga
- The West Clinic - Memphis
Arkansas
- Little Rock Hematology Oncology - Little Rock
California
- Wilshire Oncology Medical Group, Inc. - La Verne
Idaho
- North Idaho Cancer Center - Coeur d'Alene
Montana
- Hematology-Oncology Centers of the Northern Rockies - Billings
Ohio
- Mid-Ohio Oncology/Hematology - Columbus
Pennsylvania
- Pennsylvania Oncology Hematology Assoc. - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT00407563 record still lists
NCT00407563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 210-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00407563 lists 11 locations in 9 states (Georgia, Tennessee, Arkansas).
Frequently Asked Questions
What is clinical trial NCT00407563 about?
NCT00407563 is a clinical study titled "Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer". The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
What is the current status of trial NCT00407563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2007-01. Estimated completion is 2011-02.
What conditions does trial NCT00407563 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma.
What interventions are being tested in trial NCT00407563?
The interventions under investigation include: Bevacizumab (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT00407563?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00407563 being conducted?
This trial has 11 study locations across Arkansas, California, Georgia, Idaho, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00407563's enrollment target sits among peer trials
48 30th of 41 higher than 12 of 41 other Epithelial Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epithelial Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Isoquercetin in People With Ovarian Cancer
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
COMPLETED · Phase 2
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia